US Government As Represented by the Secretary of the Army

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Advanced Bioscience Laboratories, Inc.

Gary R Matyas

Carl R Alving

Mangala Rao

Nabila M Wassef

Kenner C Rice

Arthur E Jacobson

Sheetij Dutta

Malliga R Iyer

Zoltan Beck

Vaniambadi Kalyanaraman

Stephen Whitney

Thomas C VanCott

Alexander V Mayorov

Fuying Li

Victoria Polonis

Mary Marovich

Francine McCutchan

Sodsai Tovanabutra

Eric Sanders-Buell

Kejun Cheng

The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23&#xb0; C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a solublerecombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or arCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.

recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery

The instant application provides methods and related compositions pertaining to novel HIV envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel HIV envelope nucleic acid and protein sequences suitable, for example, as vaccines against HIV.

Truncated HIV envelope proteins (ENV), methods and compositions related thereto

In this application is described a composition and method for inducing in a subject anti-hapten antibodies without inducing antibodies to the carrier protein. Kits for designing and making compositions with desired haptens are also described.

Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization

The invention is a method and assay for detecting human squalene antibodies in sera or plasma using a blocking agent of &#x2212;0.5% casein in a phosphate buffered saline (PBS) solution.

Detection of human antibodies to squalene in serum

The invention is a method for detecting squalene in sera.

Detection of antibodies to squalene in serum

Growing community of inventors

Olney, MD, United States of America

Gary R Matyas